A challenge model for Shigella dysenteriae 1 in cynomolgus monkeys (Macaca fascicularis).
Steven T. Shipley(University of Maryland, Baltimore), Louis J. DeTolla(University of Maryland, Baltimore), Sofie Livio(University of Maryland, Baltimore), Milton Maciel(National Institutes of Health), Edwin H. Kriel, Hafeez Ullah Khan(Uniformed Services University of the Health Sciences), Aruna Panda(University of Maryland, Baltimore), Marcelo B. Sztein(University of Maryland, Baltimore), James P. Nataro(University of Maryland, Baltimore), Myron M. Levine(University of Maryland, Baltimore)
PubMed
February 1, 2010
Cited by 19
Related Papers
Global burden of Shigella infections: implications for vaccine development and implementation of control strategies.
|PubMed|1999|1.3k
Origins of the <i>E. coli</i> Strain Causing an Outbreak of Hemolytic–Uremic Syndrome in Germany
|New England Journal of Medicine|2011|833
Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites
|Nature|1987|503
Serum Levels of the Proinflammatory Cytokines Interleukin-1 Beta (IL-1β), IL-6, IL-8, IL-10, Tumor Necrosis Factor Alpha, and IL-12(p70) in Malian Children with Severe<i>Plasmodium falciparum</i>Malaria and Matched Uncomplicated Malaria or Healthy Controls
|Infection and Immunity|2004|447
Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road
|Nature Reviews Microbiology|2007|372